Smith & Nephew plc is a portfolio medical technology company. The Company is engaged in developing, manufacturing, marketing, and selling medical devices and services. It is focused on the repair, regeneration, and replacement of soft and hard tissue. The Company's segments include Orthopaedics, Sports Medicine & ENT and Advanced Wound Management. Its Orthopaedics segment includes a range of hip, knee and shoulder implants used to replace diseased, damaged or worn joints, robotics-assisted enabling technologies that empower surgeons, and trauma products used to stabilise severe fractures and correct bone deformities. Its Sports Medicine & Ear, Nose and Throat (ENT) businesses offer advanced products and instruments used to repair or remove soft tissue. Its Advanced Wound Management portfolio provides a comprehensive set of products to meet broad and complex clinical needs, and to help healthcare professionals reduce the human and economic consequences of wounds.
高い利益成長
同社の純利益は業界をリードしており、最新の年間純利益はUSD 5.81Bです。
高配当
同社は高配当銘柄であり、最新の配当性向は79.37%です。
安定配当
同社は過去5年間にわたり継続的に配当を実施しており、最新の配当性向は79.37%です。
割安
同社の最新のPEは30.87で、過去3年間の水準と比較して安値圏にあります。
機関投資家の売り越し
最新の機関投資家の保有株数は32.25M株で、前四半期比で24.19%減少しています。
レイ・ダリオが保有
スター投資家レイ・ダリオは本銘柄を203.99K株保有しています。